Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04957550
PHASE3

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

418

Start Date

2021-08-30

Completion Date

2026-12-13

Last Updated

2026-08-28

Healthy Volunteers

No

Interventions

DRUG

SHR0302 tablets、Placebo

SHR0302 tablets dose 1 for 48 weeks

DRUG

SHR0302 tablets、Placebo

SHR0302 tablets dose 2 for 48 weeks

DRUG

Placebo

SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks

Locations (1)

Peking University Hospital

Beijing, Beijing Municipality, China